Sei Yoshida

594 citations

22 papers · 395 · h-index 11

Impact in

Computational Theory and Mathematics top 10%
- Computational Drug Discovery Methods
Oncology
- Cytokine Signaling Pathways and Interactions
- HER2/EGFR in Cancer Research

Papers in

Molecular Biology 15
- Melanoma and MAPK Pathways 6
- Cell death mechanisms and regulation 4
- RNA Interference and Gene Delivery 3
- Cancer therapeutics and mechanisms 3
Organic Chemistry 8
- Synthesis and biological activity 5

Co-authors: Tomoyasu Ishikawa (13 shared papers)Masanori Okaniwa (7 shared papers)Takeo Arita (7 shared papers)Akito Nakamura (5 shared papers)Masato Yabuki (9 shared papers)Jill Donelan (1 shared paper)Elizabeth Carideo (1 shared paper)Kenichiro Naito (4 shared papers)
Journals: Bioorganic & Medicinal Chemistry (6 papers)Molecular Cancer Therapeutics (3 papers)Biochemical and Biophysical Research Communications (2 papers)Pharmaceutics (2 papers)Journal of Controlled Release (2 papers)
Partner nations: Japan United States Cyprus

In The Last Decade

Sei Yoshida

22 papers receiving 390 citations

Peers

Countries citing papers authored by Sei Yoshida

Since Specialization

Citations

This map shows the geographic impact of Sei Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sei Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sei Yoshida more than expected).

Fields of papers citing papers by Sei Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sei Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sei Yoshida. The network helps show where Sei Yoshida may publish in the future.

Co-authors

The 25 scholars most cited alongside Sei Yoshida, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sei Yoshida Line = papers co-authored together Sei Yoshida links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma Cancer Research ·Akito Nakamura, Takeo Arita, Shuntarou Tsuchiya, Jill Donelan, Jouhara Chouitar, Elizabeth Carideo, Katherine Galvin, Masanori Okaniwa, Tomoyasu Ishikawa, Sei Yoshida	2013	100
2	Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives Journal of Medicinal Chemistry ·Masanori Okaniwa, Masaaki Hirose, Takeo Arita, Masato Yabuki, Akito Nakamura, Terufumi Takagi, Tomohiro Kawamoto, Noriko Uchiyama, Akihiko Sumita, Shunichirou Tsutsumi, Tsuneaki Tottori, Yoshitaka Inui, Bi‐Ching Sang, Jason K. Yano, Kathleen Aertgeerts, Sei Yoshida, Tomoyasu Ishikawa	2013	93
3	Novel HER2 selective tyrosine kinase inhibitor, TAK‐165, inhibits bladder, kidney and androgen‐independent prostate cancer in vitro and in vivo International Journal of Urology ·Jôji Nagasawa, Atsushi Mizokami, Kiyoshi Koshida, Sei Yoshida, Kenichiro Naito, Mikio Namiki	2006	54
4	Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment Journal of Controlled Release ·Fotios Mpekris, Myrofora Panagi, Christina Michael, Chrysovalantis Voutouri, Masami Tsuchiya, Chihiro Wagatsuma, Hiroaki Kinoh, Atsushi Osada, Shiro Akinaga, Sei Yoshida, John D. Martin, Triantafyllos Stylianopoulos	2022	18
5	Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells Bioorganic & Medicinal Chemistry ·Zenyu Shiokawa, Kentaro Hashimoto, Bunnai Saito, Yuya Oguro, Hiroyuki Sumi, Masato Yabuki, Mie Yoshimatsu, Yohei Kosugi, Yasuyuki Debori, Nao Morishita, Douglas R. Dougan, G. Snell, Sei Yoshida, Tomoyasu Ishikawa	2013	17
6	Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones Bioorganic & Medicinal Chemistry ·Osamu Kurasawa, Yuya Oguro, T. Miyazaki, Misaki Homma, Kouji Mori, Kenichi Iwai, Hideto Hara, R.J. Skene, Isaac Hoffman, Akihiro Ohashi, Sei Yoshida, Tomoyasu Ishikawa, Nobuo Cho	2017	15
7	Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects Journal of Controlled Release ·Hiroki Takashima, Yoshikatsu Koga, Ryo Tsumura, Masahiro Yasunaga, Masami Tsuchiya, Tadashi Inoue, Eriko Negishi, Mitsunori Harada, Sei Yoshida, Yasuhiro Matsumura	2020	14
8	Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives Bioorganic & Medicinal Chemistry ·Masaaki Hirose, Masanori Okaniwa, T. Miyazaki, Takashi Imada, Tomohiro Ohashi, Yuta Tanaka, Takeo Arita, Masato Yabuki, Tomohiro Kawamoto, Shunichirou Tsutsumi, Akihiko Sumita, Terufumi Takagi, Bi‐Ching Sang, Jason K. Yano, Kathleen Aertgeerts, Sei Yoshida, Tomoyasu Ishikawa	2012	13
9	2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase Bioorganic & Medicinal Chemistry ·Osamu Kurasawa, Misaki Homma, Yuya Oguro, T. Miyazaki, Kouji Mori, Noriko Uchiyama, Kenichi Iwai, Akihiro Ohashi, Hideto Hara, Sei Yoshida, Nobuo Cho	2017	12
10	Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins Molecular Cancer Therapeutics ·Hiroyuki Sumi, Masato Yabuki, Kenichi Iwai, Megumi Morimoto, Ryosuke Hibino, Masakazu Inazuka, Kentaro Hashimoto, Yohei Kosugi, Kazunobu Aoyama, S. Yamamoto, Mie Yoshimatsu, Hideki Yamasaki, Ryuichi Tozawa, Tomoyasu Ishikawa, Sei Yoshida	2012	12
11	Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists Bioorganic & Medicinal Chemistry ·Moriteru Asano, Kentaro Hashimoto, Bunnai Saito, Zenyu Shiokawa, Hiroyuki Sumi, Masato Yabuki, Mie Yoshimatsu, Kazunobu Aoyama, Teruki Hamada, Nao Morishita, Douglas R. Dougan, Clifford D. Mol, Sei Yoshida, Tomoyasu Ishikawa	2013	11
12	An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) Biochemical and Biophysical Research Communications ·Hiroyuki Sumi, Masakazu Inazuka, Megumi Morimoto, Ryosuke Hibino, Kentaro Hashimoto, Tomoyasu Ishikawa, Keisuke Kuida, Peter G. Smith, Sei Yoshida, Masato Yabuki	2016	9
13	Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption Bioorganic & Medicinal Chemistry ·Masanori Okaniwa, Takashi Imada, Tomohiro Ohashi, T. Miyazaki, Takeo Arita, Masato Yabuki, Akihiko Sumita, Shunichirou Tsutsumi, Keiko Higashikawa, Terufumi Takagi, Tomohiro Kawamoto, Yoshitaka Inui, Sei Yoshida, Tomoyasu Ishikawa	2012	8
14	Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET Pharmaceutics ·Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii	2022	4
15	Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates Pharmaceuticals ·Hiroki Matsumoto, Tadashi Watabe, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Atsuo Waki, Ming‐Rong Zhang, Hideaki Tashima, Taiga Yamaya, Kazuhiro Ooe, Eku Shimosegawa, Jun Hatazawa, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii	2021	4
16	Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography Pharmaceutics ·Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Atsuo Waki, Ming‐Rong Zhang, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, Kimiteru Ito, Tatsuya Higashi, Yukie Yoshii	2021	3
17	Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC. Molecular Cancer Therapeutics ·Elizabeth Grace Carideo Cunniff, Julie Zhang, Jouhara Chouitar, Jerome T. Mettetal, Kazuhide Nakamura, Takeo Arita, Akito Nakamura, Masanori Okaniwa, Tomoyasu Ishikawa, Sei Yoshida, Robyn Fabrey, Patrick W. Vincent, Kurt Eng, Khristofer Garcia, Deanna Borelli, Teena Vagrhese, Steve Stroud, Saurabh Menon, Mike Kuranda, Katherine Galvin	2013	2
18	T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production Biochemical and Biophysical Research Communications ·Hiroyuki Sumi, Masakazu Inazuka, Kentaro Hashimoto, Tomoyasu Ishikawa, Sei Yoshida, Masato Yabuki	2016	2
19	Abstract C255: Discovery of TAK-632: A selective kinase inhibitor of pan-RAF with potent antitumor activity against BRAF and NRAS mutant melanomas. Molecular Cancer Therapeutics ·Masanori Okaniwa, Masaaki Hirose, Takeo Arita, Masato Yabuki, Akito Nakamura, Terufumi Takagi, Tomohiro Kawamoto, Noriko Uchiyama, Akihiko Sumita, Shunichirou Tsutsumi, Tsuneaki Tottori, Yoshitaka Inui, Bi‐Ching Sang, Jason K. Yano, Kathleen Aertgeerts, Sei Yoshida, Tomoyasu Ishikawa	2013	1
20	Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC. Journal of Clinical Oncology ·Elizabeth Grace Carideo Cunniff, Julie Zhang, Jouhara Chouitar, Jerome T. Mettetal, Kazuhide Nakamura, Takeo Arita, Akito Nakamura, Masanori Okaniwa, Tomoyasu Ishikawa, Sei Yoshida, Robyn Fabrey, Patrick W. Vincent, Kurt Eng, Khristofer Garcia, Deanna Borrelli, Teena Vagrhese, Steve Stroud, Saurabh Menon, Mike Kuranda, Katherine Galvin	2013	1

About Sei Yoshida

Sei Yoshida is a scholar working on Molecular Biology, Organic Chemistry, Oncology, Computational Theory and Mathematics and Radiology, Nuclear Medicine and Imaging, having authored 22 papers that have together received 395 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (6 papers), Synthesis and biological activity (5 papers), Cell death mechanisms and regulation (4 papers), Computational Drug Discovery Methods (4 papers), RNA Interference and Gene Delivery (3 papers), Cancer therapeutics and mechanisms (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Nanoparticle-Based Drug Delivery (2 papers). The work is most often cited by research in Computational Theory and Mathematics (75 citations), Oncology (106 citations), Molecular Biology (279 citations), Pathology and Forensic Medicine (52 citations) and Organic Chemistry (87 citations). Sei Yoshida has collaborated with scholars based in Japan, United States and Cyprus. Frequent co-authors include Tomoyasu Ishikawa, Masanori Okaniwa, Takeo Arita, Akito Nakamura, Masato Yabuki, Jill Donelan, Elizabeth Carideo, Kenichiro Naito, Katherine Galvin and Atsushi Mizokami. Their work appears in journals such as Bioorganic & Medicinal Chemistry, Molecular Cancer Therapeutics, Biochemical and Biophysical Research Communications, Pharmaceutics and Journal of Controlled Release.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Sei Yoshida

Impact in

Papers in i

In The Last Decade

Sei Yoshida

Peers

Countries citing papers authored by Sei Yoshida

Fields of papers citing papers by Sei Yoshida

All Works

About Sei Yoshida

Explore authors with similar magnitude of impact

Papers in